SHC
Sotera HealthBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-11
Current thesis
Sotera executes on cost‑savings and margin initiatives, European pricing stabilizes, and secondary float pressure subsides — enabling ~50%+ upside from current levels as organic growth and higher utilization drive EBITDA expansion.
Posture
Constructive
Lead driver
Value
What changed
3 setup hits (3d) with net bullish as of 2026-06-10.
What can break
2026 debt maturities and refinancing risk
Momentum
55
Value
63
Sentiment
58
Setup hits (3d)
3 · Net Bullish
AI TargetsBase $17.64 · Bull $26.46 · Bear $12.35
Data freshness
Prices
As of 2026-06-11
Fundamentals
As of 2026-06-09 • Vendor: Data Vendor v1
Scores
As of 2026-06-11 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-01 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-11
Investment thesis
As of 2026-06-11
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Bullish
Target $20.75
Why
Momentum55 · Δ7d +1.8
Value63 · Δ7d -0.4
Sentiment58 · Δ7d -11.4
So what
Strength-led posture (Net Bullish). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
55
34% active weight
Current posture
7d trendImproving
Δ7d
+1.8
Δ21d
+3.5
Value
63
32% active weight
Current posture
7d trendFlat
Δ7d
-0.4
Δ21d
-0.2
Sentiment
58
33% active weight
Current posture
7d trendSoftening
Δ7d
-11.4
Δ21d
-6.2
Why this grade
Composite grade B. Momentum 54.5 / Value 63.0 / Sentiment 58.3
Fundamentals (TTM)As of 2026-06-09
Fundamentals (TTM)
As of 2026-06-09
Market Cap
$4.71B
Beta
1.82
Shares Out
284.09M
P/E (TTM)
94.8
P/S (TTM)
4.52
P/FCF (TTM)
60.02
Rev YoY
+9.1%
EPS YoY
+183.7%
Gross Margin
+56.0%
Op Margin
+24.1%
Net Debt
$2.04B
Current Ratio
2.38
As of 2026-06-11 • Updated nightlySource: Internal modelMethodology